Re: A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia

On Jun 25, 2:19 pm, Susan <neverm...@xxxxxxxxxx> wrote:
x-no-archive: yes

MarilynMann wrote:
The two studies in pediatric patients with heFH that I know of that
are currently underway are both sponsored by drug companies.

1. A study of colesevelam in kids with heFH who are on a statin or
who are treatment-naive to lipid-lowering therapy. Endpoints relate
to percentage change in LDL. Sponsored by Daiichi Sankyo.

Sickening that children would be unnecessarily exposed to a toxic
substance to reach a measurable endpoint that's pretty meaningless in
terms of their health.



2. A study of rosuvastatin vs. placebo. Primary endpoint is percent
change in LDL from baseline to end of treatment phase (12 weeks).
Secondary endpoints are percent change in LDL and other lipids from
baseline to week 6 and at week 12. Also, percent control rate based
on achievement of LDL target of <110. There is a 40-week open-label
follow-up. Sponsor: AstraZeneca.

*SIGH*



Neither of these studies seems that interesting to me.

They interest me the way any child abuse does.

Susan

Well, they are just trying to sell their products. The results seem
fairly unimportant. I don't care if they get their LDL down to 70.
In addition, trials of bile acid sequestrants with clinical endpoints
did not show favorable results on total mortality.

Marilyn

.

Relevant Pages